Health X Platform Ltd

- SastaSundar Ventures Limited does not project to raise any capital (debt or equity) in the next 2-3 years. - The company aims to be self-sufficient and focus fully on building the business without spending management bandwidth on fundraising. - Current investments are funded through treasury income and operational cash flows. - The company emphasizes capital efficiency and managing growth through existing resources rather than external funding. - Any experimentation or innovation is done with small capital to control costs and risks. - The management advises investors to be patient over the next 5 years, as the company is still in an early stage with high growth potential but also significant execution risks.

- SastaSundar plans to invest around INR150 crores primarily in technology, supply chain, and warehouse capabilities over FY '25 and FY '26. - In FY '25, INR35 crores were invested in the technology team and advertisement, matching projections. - FY '26 projection includes around INR50 crores investment mainly directed towards building the technology platform and AI capabilities. - Treasury income will cover about INR50 crores investment in SastaSundar, aiming for self-sufficiency without raising new capital for at least 2-3 years. - Capital allocation is cautious, focusing on small-scale experiments with low failure costs for learning. - Future investments depend on achieving profitability in RetailerShakti and validation of the SastaSundar B2C model. - No plans for capital raising in the near term; management prioritizes building the business over fundraising activities.

- SastaSundar estimates 100% growth in B2C segment for FY '26 compared to FY '25. - RetailerShakti B2B business nearly doubled revenue from INR489 crores in FY '24 to approx. INR941 crores in FY '25. - Target positive EBITDA margin of 1% for RetailerShakti by Q4 FY '26. - Aim for blended EBITDA margin between 4% to 5% by FY '30, with SastaSundar targeting 7% and RetailerShakti around 4%. - Long-term vision to scale rapidly with a highly scalable and sustainable model. - Focus on building innovative digital healthcare products and AI-driven tools to enhance customer engagement. - Cautious approach advised; company still in startup infancy stage, recommending investors to be patient for at least 5 years. - No capital raising planned in next 2-3 years, focusing on self-sufficiency and efficient capital investment.

- FY '26: Targeting RetailerShakti to achieve positive EBITDA margin (~1% in the last quarter), continuing investment of INR45-50 crores in SastaSundar B2C. - FY '30: Aiming for blended EBITDA margin between 4% to 5%, with SastaSundar targeting 7% EBITDA margin and RetailerShakti around 4%. - Growth drivers include doubling B2C revenue in FY '26, scaling RetailerShakti network and profitability balance. - The business is in startup infancy; investors advised to adopt a long-term view (5 years) due to execution risks and growth phase. - Capital efficiency and positive cash flow are emphasized, with no planned capital raising for 2-3 years. - Expansion of AI-driven healthcare tools and diagnostic integration expected to enhance customer value and revenue streams. - Management prioritizes sustainable growth and profitability over short-term quarterly results.

The transcript does not explicitly mention current or expected orderbook or pending orders for SastaSundar Ventures Limited. However, relevant insights related to business growth and operations include: - RetailerShakti revenue nearly doubled in FY '25, indicating strong order growth and network expansion. - The company is focusing on scaling both B2B (RetailerShakti) and B2C (SastaSundar) businesses, with B2C still in nascent stage. - Plans to invest around INR 150 crores over two years for platform and warehouse capabilities to support growth. - They expect 100% growth in B2C revenues in FY '26, doubling from last year. - Focus on operational efficiency, supply chain, and customer demand fulfillment to sustainably increase order volumes. - No explicit mention of pending order backlog or orderbook figures in the transcript.